BETHESDA, Md., Dec. 7, 2010 /PRNewswire/ -- The Foundation for the National Institutes of Health's Biomarkers Consortium announced today that the results of a proteomics study performed utilizing plasma samples from the Alzheimer's Disease Neuroimaging Initiative (ADNI) are ready to be shared with scientists worldwide for further analysis.
This study represents the work of the Biomarkers Consortium Project Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimer's Disease. This project is intended to be the first part of a multi-phased effort seeking to utilize samples collected by ADNI to qualify multiplex panels in both plasma and cerebrospinal fluid (CSF) to diagnose patients with Alzheimer's disease (AD) and monitor disease progression.
This data is available to the scientific community for download and further analysis via the ADNI website, http://adni.loni.ucla.edu; more specific information about this data is available at http://adni.loni.ucla.edu/wp-content/uploads/2010/11/BC_Plasma_Proteomics_Data_Primer.pdf.
"We are pleased to announce the release of this data, which represents a critical step towards the completion of this project," remarked Scott E. Campbell, Ph.D., Executive Director and CEO of the Foundation for NIH. "This project provides further evidence that academia, industry, and government can work closely together on projects that require the input and involvement of these diverse sectors."
This Biomarkers Consortium project utilized plasma samples gathered by ADNI, a $60 million project launched in 2004 which concludes by the end of 2010, which is a public-private partnership supported primarily by the National Institutes of Health (NIH) with pharmaceutical, imaging and clinical trial management compa